West Pharmaceutical Services, Inc.

WST · NYSE · USD

PoliticiansInstitutionalInsiders

Current holders

Politician	Disclosed
Donald Trump R · EXECUTIVE	net — – — 1 disclosure · 1 bought / 0 sold · last Feb 10, 2026
Lamar Smith R · HOUSE · TX	$3K – $45K $13K – $190K today 3 filings · last Apr 30, 2018
Jared Moskowitz D · HOUSE · FL	−$27K – $43K −$44K – $45K today 5 filings · last Feb 13, 2025
Lisa C. McClain R · HOUSE · MI	−$14K – $14K −$25K – $25K today 2 filings · last Jul 22, 2025
Tommy Tuberville R · SENATE · AL	−$14K – $14K −$13K – $20K today 2 filings · last Mar 30, 2022
Robert Bresnahan R · HOUSE · PA	−$14K – $14K −$29K – $25K today 2 filings · last Apr 8, 2025
Greg Gianforte R · HOUSE · MT	−$65K – $49K −$45K – $242K today 3 filings · last Sep 24, 2020
Ro Khanna D · HOUSE · CA	−$264K – $135K −$339K – $199K today 27 filings · last Jun 2, 2026

Recent transactions

Trades from Sep 24, 2020 – Jun 2, 2026

Politician	Type	Filed after	Amount
Ro Khanna D · HOUSE · CA-17	Sell	34 days Jun 2, 2026 → Jul 6, 2026	≥$1K
Ro Khanna D · HOUSE · CA-17	Sell	13 days May 27, 2026 → Jun 9, 2026	≥$1K
Donald Trump R · EXECUTIVE	Buy	92 days Feb 10, 2026 → May 13, 2026	≥$250K
Ro Khanna D · HOUSE · CA-17	Sell	32 days Feb 5, 2026 → Mar 9, 2026	≥$1K
Ro Khanna D · HOUSE · CA-17	Buy	8 days Jan 29, 2026 → Feb 6, 2026	≥$1K
Lisa C. McClain R · HOUSE · MI-9	Sell	22 days Jul 22, 2025 → Aug 13, 2025	≥$1K
Lisa C. McClain R · HOUSE · MI-9	Buy	57 days Jun 17, 2025 → Aug 13, 2025	≥$1K
Ro Khanna D · HOUSE · CA-17	Buy	22 days May 19, 2025 → Jun 10, 2025	≥$1K
Ro Khanna D · HOUSE · CA-17	Buy	19 days Apr 23, 2025 → May 12, 2025	≥$1K
Robert Bresnahan R · HOUSE · PA-8	Sell	30 days Apr 8, 2025 → May 8, 2025	≥$1K

Congressional trading data provided by QuiverQuant

Institutional

Investors holding

856

13F shares

71.1M

Total invested

$25.5B

Ownership

98.7%

New positions

153

Closed positions

Increased positions

454

Reduced positions

265

Put/Call ratio

0.61

Holder	Reported	Shares	Value	Δ Qtr
BLACKROCK, INC.	8/7/2026	6.7M	$2.4B	−2.71%
VANGUARD CAPITAL MANAGEMENT LLC	8/13/2026	4.6M	$1.7B	−1.50%
VANGUARD PORTFOLIO MANAGEMENT LLC	8/13/2026	4M	$1.4B	−1.91%
FMR LLC	8/13/2026	3.6M	$1.3B	+186.04%
STATE STREET CORP	9/22/2026	3.3M	$1.2B	+1.67%
ARTISAN PARTNERS LIMITED PARTNERSHIP	8/13/2026	2.4M	$865.8M	−9.26%
BANK OF NEW YORK MELLON CORP	8/6/2026	2M	$733.7M	−17.12%
GENERATION INVESTMENT MANAGEMENT LLP	8/10/2026	2M	$728.2M	−9.61%
GEODE CAPITAL MANAGEMENT, LLC	8/12/2026	1.9M	$680.6M	−0.48%
T. ROWE PRICE INVESTMENT MANAGEMENT, INC.	8/14/2026	1.8M	$648.0M	−22.88%
MORGAN STANLEY	8/13/2026	1.6M	$568.1M	+8.52%
JPMORGAN CHASE & CO	8/12/2026	1.2M	$413.0M	+11.61%
BROWN ADVISORY INC	8/14/2026	1.1M	$386.0M	−19.81%
LONGVIEW PARTNERS (GUERNSEY) LTD	8/13/2026	1M	$371.1M	−21.41%
INVESCO LTD.	8/14/2026	1M	$362.5M	−4.37%
UBS ASSET MANAGEMENT AMERICAS INC	8/13/2026	884.9K	$317.7M	−1.98%
NORGES BANK	8/12/2026	862.9K	$309.8M	—
GOLDMAN SACHS GROUP INC	8/14/2026	814.8K	$292.5M	+11.98%
KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC	8/13/2026	760.6K	$273.1M	−11.38%
TD ASSET MANAGEMENT INC	8/4/2026	731.1K	$262.4M	−4.93%
NORTHERN TRUST CORP	8/13/2026	709.4K	$254.7M	−2.99%
CAPITAL RESEARCH GLOBAL INVESTORS	8/12/2026	609.2K	$218.7M	+0.86%
VAN ECK ASSOCIATES CORP	8/14/2026	604.8K	$217.1M	−15.25%
PROSHARE ADVISORS LLC	8/11/2026	598K	$214.7M	−9.40%
FINDLAY PARK PARTNERS LLP	8/12/2026	596.6K	$214.2M	−3.26%

Insider transactions

No recent insider transactions for this stock.

Analyst consensus

Buy17 analysts

Bearish · 1 · Hold · 2 · Bullish · 14

Earnings history

	EPS	Estimate
Q3 2024	$1.85	$1.50	Beat
Q4 2024	$1.82	$1.71	Beat
Q1 2025	$1.45	$1.22	Beat
Q2 2025	$1.84	$1.51	Beat
Q3 2025	$1.96	$1.68	Beat
Q4 2025	$2.04	$1.83	Beat
Q1 2026	$2.13	$1.68	Beat
Q2 2026	$2.37	$2.08	Beat

Peers

Company overview

IPO dateMar 17, 1980

CEOMichel Lagarde

Employees10,800

SectorHealthcare

IndustryMedical - Instruments & Supplies

CountryUS

ExchangeNew York Stock Exchange

Websitewww.westpharma.com

West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies. This segment further supplies ancillary services such as specialized films, protective coatings, cleaning, precision vision inspection, and sterilization processes to elevate the quality of packaging components. Innovative drug containment options, like Crystal Zenith – a cyclic olefin polymer used in vials, syringes, and cartridges – and user-friendly self-injection devices are also key offerings. Additionally, it provides a suite of integrated support services covering analytical laboratory analysis, primary packaging assistance during the pre-approval stage, engineering development, regulatory guidance, and post-purchase technical support. Its clientele primarily includes manufacturers of biologic, generic, and other pharmaceutical products. In contrast, the Contract-Manufactured Products division focuses on the design, production, and automated assembly of various devices for surgical, diagnostic, ophthalmic, and general drug delivery applications, alongside consumer items. This segment caters to pharmaceutical, diagnostic, and medical device manufacturers. The company's offerings reach customers worldwide through a dedicated sales team, an extensive distribution network, and partnerships with contract sales agents and regional distributors. Established in 1923, West Pharmaceutical Services, Inc. is headquartered in Exton, Pennsylvania.

Athenic provides research and information tools for educational purposes only and is not a registered investment adviser or broker-dealer. Nothing on this page is investment advice or a recommendation to buy or sell any security. Market data may be delayed. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal.